Open-label phase 1b/2 trial of navenibart, a long-acting plasma kallikrein inhibitor for hereditary angioedema.
- DOI
- 10.1016/j.jaci.2026.02.034
- Published
- 2026 May
- Container
- The Journal of allergy and clinical immunology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.jaci.2026.02.034,
title = {Open-label phase 1b/2 trial of navenibart, a long-acting plasma kallikrein inhibitor for hereditary angioedema.},
author = {Banerji A and Craig T and Sitz K and Li HH and Lumry W and Adatia A and Yang W and Jacobs JS and Tachdjian R and Soong W and Manning M and Wedner J and Savic S and Manson A and Valerieva A and Gunsior M and Mugundu G and Cohen T and Bernard K and VanEenwyk C and Joseph K and Best JM and Morabito C and Riedl MA},
year = {2026},
journal = {The Journal of allergy and clinical immunology},
doi = {10.1016/j.jaci.2026.02.034},
url = {https://doi.org/10.1016/j.jaci.2026.02.034}
}RIS
TY - JOUR TI - Open-label phase 1b/2 trial of navenibart, a long-acting plasma kallikrein inhibitor for hereditary angioedema. AU - Banerji A AU - Craig T AU - Sitz K AU - Li HH AU - Lumry W AU - Adatia A AU - Yang W AU - Jacobs JS AU - Tachdjian R AU - Soong W AU - Manning M AU - Wedner J AU - Savic S AU - Manson A AU - Valerieva A AU - Gunsior M AU - Mugundu G AU - Cohen T AU - Bernard K AU - VanEenwyk C AU - Joseph K AU - Best JM AU - Morabito C AU - Riedl MA PY - 2026 JO - The Journal of allergy and clinical immunology DO - 10.1016/j.jaci.2026.02.034 UR - https://doi.org/10.1016/j.jaci.2026.02.034 ER -
APA
A, B., T, C., K, S., HH, L., W, L., A, A., W, Y., JS, J., R, T., W, S., M, M., J, W., S, S., A, M., A, V., M, G., G, M., T, C., K, B., C, V., K, J., JM, B., C, M., & MA, R. (2026). Open-label phase 1b/2 trial of navenibart, a long-acting plasma kallikrein inhibitor for hereditary angioedema.. The Journal of allergy and clinical immunology. https://doi.org/10.1016/j.jaci.2026.02.034
Source records
- pubmed · retrieved 2026-09-27T07:43:41.694Z